Evaluation of the YSI 2300 glucose analyzer: algorithm-corrected results are accurate and specific

Area of Science:

• Clinical chemistry
• Biomedical instrumentation
• Diagnostic assay development

Background:

• Accurate glucose measurement is crucial for diabetes management.
• Commutability between whole blood and plasma glucose assays is essential for consistent patient care.
• Glucose oxidase methods can be susceptible to interferences from various compounds and hematocrit variations.

Purpose of the Study:

• To evaluate the commutability of whole blood glucose measurements with plasma glucose values.
• To assess the performance of different glucose analyzers and hematocrit correction methods.
• To identify potential interferences in glucose oxidase-based methods.

Main Methods:

• Comparison of plasma glucose results from the Ektachem 700 analyzer with whole blood glucose results from the Nova Stat Profile 6 and YSI 2300 analyzers.
• Evaluation of two hematocrit (Hct) correction methods for the YSI 2300: multiplication by 1.11 (YSI1.11) and an algorithm-based correction (YSIcor).
• Testing for interference from various chemical compounds on the analyzers.

Main Results:

• The YSI algorithm-corrected (YSIcor) whole blood glucose results showed 88% agreement within ±5% of plasma results.
• YSIcor results were unaffected by hematocrit variations and abnormal erythrocyte size.
• The Nova analyzer showed falsely decreased results at low Hct, while YSI1.11 showed falsely elevated results. Ascorbic acid interfered with Ektachem, and acetaminophen interfered with Nova.

Conclusions:

• The YSI algorithm-corrected whole blood glucose measurements are commutable with plasma glucose results.
• The YSI 2300 analyzer, with its algorithm-based hematocrit correction, demonstrated robustness against tested interferences, including acetaminophen and acetylsalicylic acid.
• This validated method ensures reliable glucose monitoring across different sample conditions.